Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Environmental Factors Instruct Lineage Choice Of Blood Progenitor Cells
The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum MÃønchen, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.

Nanoparticles Target Ovarian Cancer At MIT
Tiny particles carrying a killer gene can effectively suppress ovarian tumor growth in mice, according to a team of researchers from MIT and the Lankenau Institute.
News of the day
Research Proves Tai Chi Benefits For Arthritis
A new study by The George Institute for International Health has found Tai Chi to have positive health benefits for musculoskeletal pain. The results of the first comprehensive analysis of Tai Chi suggest that it produces positive effects for improving pain and disability among arthritis sufferers.
Nutrition

New Promise For Sleeping Sickness Treatment

NECT (Nifurtimox-Eflornithine Combination Therapy), a new treatment option for sleeping sickness, a fatal disease that threatens 60 million people across sub-Saharan Africa, has been added to the Essential Medicines List (EML) of the World Health Organization (WHO). The inclusion is based on an application submitted by the non-profit Drugs for Neglected Diseases initiative (DNDi), supported by the international medical humanitarian organization Doctors Without Borders/Mç©decins Sans Frontiç¨res (MSF), and Epicentre, MSF"s epidemiological research center. According to the WHO, NECT can now be used in patients and will provide an opportunity to improve the management of sleeping sickness cases. WHO has already made preparations for the arrival of this improved therapeutic opportunity and will work to ensure that patients have access to NECT by providing appropriate training and by supplying the drugs and necessary equipment to disease-endemic countries. NECT, a co-administration schedule of oral nifurtimox and intravenous eflornithine, is made available through donations to WHO by Sanofi-Aventis (eflornithine) and Bayer (nifurtimox). A pivotal, five-year long Phase III study comparing NECT with eflornithine used alone was recently completed by a partnership including Epicentre, MSF, DNDi, the Swiss Tropical Institute, and the national sleeping sickness control programs of the Republic of the Congo and the Democratic Republic of the Congo. "This study was built on previous Epicentre and MSF studies that identified this particular drug combination as a promising therapy," said Emmanuel Baron, director of Epicentre. "It has provided some of the strongest evidence in sleeping sickness research to date, and has demonstrated NECT to be a better treatment option for advanced-stage sleeping sickness, as compared with the two current treatments which are either toxic or too complicated to use." "NECT is critical in our efforts to address the needs of neglected patients suffering from a fatal disease," said Christophe Fournier, president of MSF"s international council. "This improved treatment needs to be rolled out urgently to replace the current, most commonly used therapy that kills one in every 20 patients." "We at DNDi welcome this decision and the rallying by the sleeping sickness community in support of this application as it underscores the practical improvement and impact NECT can make in the field today," said Bernard Pç©coul, executive director of DNDi. "No new drugs for stage two sleeping sickness are expected in the next five years, so there is an urgent need to develop new treatments based on currently available drugs, especially through combinations. However, even with the importance of this development, we have made but one step on the path to ultimately meeting patient needs." Click here to access WHO information about NECT inclusion onto the Essential Medicines List Doctors Without Borders/Mç©decins Sans Frontiç¨res (MSF)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009